NASDAQ:FBIO

Fortress Biotech Competitors

$4.12
-0.32 (-7.21 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$4.00
Now: $4.12
$4.34
50-Day Range
$3.40
MA: $4.17
$5.48
52-Week Range
$1.89
Now: $4.12
$6.10
Volume1.97 million shs
Average Volume1.69 million shs
Market Capitalization$391.02 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43

Competitors

Fortress Biotech (NASDAQ:FBIO) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying FBIO stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Fortress Biotech, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Fortress Biotech (NASDAQ:FBIO) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Fortress Biotech and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fortress Biotech00603.00
Amgen091402.61

Fortress Biotech presently has a consensus target price of $10.75, suggesting a potential upside of 160.92%. Amgen has a consensus target price of $261.0476, suggesting a potential upside of 2.09%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Amgen.

Valuation and Earnings

This table compares Fortress Biotech and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$36.63 million10.67$-39,960,000.00($0.73)-5.64
Amgen$23.36 billion6.30$7.84 billion$14.8217.25

Amgen has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fortress Biotech and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fortress Biotech-131.98%-44.08%-19.06%
Amgen29.42%95.55%15.52%

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Institutional & Insider Ownership

32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Amgen beats Fortress Biotech on 9 of the 14 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Fortress Biotech and Gilead Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fortress Biotech00603.00
Gilead Sciences191302.52

Fortress Biotech presently has a consensus target price of $10.75, suggesting a potential upside of 160.92%. Gilead Sciences has a consensus target price of $97.92, suggesting a potential upside of 46.43%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Gilead Sciences.

Valuation and Earnings

This table compares Fortress Biotech and Gilead Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$36.63 million10.67$-39,960,000.00($0.73)-5.64
Gilead Sciences$22.45 billion3.75$5.39 billion$6.1410.89

Gilead Sciences has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fortress Biotech and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fortress Biotech-131.98%-44.08%-19.06%
Gilead Sciences5.48%37.77%12.76%

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Institutional & Insider Ownership

32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 0.1% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Gilead Sciences beats Fortress Biotech on 9 of the 14 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Fortress Biotech and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fortress Biotech00603.00
Vertex Pharmaceuticals042112.88

Fortress Biotech presently has a consensus target price of $10.75, suggesting a potential upside of 160.92%. Vertex Pharmaceuticals has a consensus target price of $293.1250, suggesting a potential upside of 33.61%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Vertex Pharmaceuticals.

Valuation and Earnings

This table compares Fortress Biotech and Vertex Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$36.63 million10.67$-39,960,000.00($0.73)-5.64
Vertex Pharmaceuticals$4.16 billion13.64$1.18 billion$4.2951.14

Vertex Pharmaceuticals has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fortress Biotech and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fortress Biotech-131.98%-44.08%-19.06%
Vertex Pharmaceuticals38.51%28.55%20.68%

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Institutional & Insider Ownership

32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Fortress Biotech on 11 of the 15 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Institutional & Insider Ownership

32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Fortress Biotech and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fortress Biotech00603.00
Regeneron Pharmaceuticals051412.80

Fortress Biotech presently has a consensus target price of $10.75, suggesting a potential upside of 160.92%. Regeneron Pharmaceuticals has a consensus target price of $646.2609, suggesting a potential upside of 28.58%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Regeneron Pharmaceuticals.

Valuation and Earnings

This table compares Fortress Biotech and Regeneron Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$36.63 million10.67$-39,960,000.00($0.73)-5.64
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41

Regeneron Pharmaceuticals has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares Fortress Biotech and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fortress Biotech-131.98%-44.08%-19.06%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Summary

Regeneron Pharmaceuticals beats Fortress Biotech on 10 of the 15 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

32.1% of Fortress Biotech shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 29.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Fortress Biotech and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fortress Biotech00603.00
Biogen5141202.23

Fortress Biotech presently has a consensus price target of $10.75, suggesting a potential upside of 160.92%. Biogen has a consensus price target of $303.5862, suggesting a potential upside of 12.31%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Biogen.

Earnings & Valuation

This table compares Fortress Biotech and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$36.63 million10.67$-39,960,000.00($0.73)-5.64
Biogen$14.38 billion2.86$5.89 billion$33.578.05

Biogen has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares Fortress Biotech and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fortress Biotech-131.98%-44.08%-19.06%
Biogen35.63%51.00%23.54%

Summary

Biogen beats Fortress Biotech on 9 of the 14 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

32.1% of Fortress Biotech shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 29.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Fortress Biotech and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fortress Biotech00603.00
Alexion Pharmaceuticals017512.30

Fortress Biotech presently has a consensus price target of $10.75, suggesting a potential upside of 160.92%. Alexion Pharmaceuticals has a consensus price target of $153.8636, suggesting a potential downside of 6.00%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Fortress Biotech and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$36.63 million10.67$-39,960,000.00($0.73)-5.64
Alexion Pharmaceuticals$4.99 billion7.21$2.40 billion$9.7416.80

Alexion Pharmaceuticals has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Fortress Biotech has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Profitability

This table compares Fortress Biotech and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fortress Biotech-131.98%-44.08%-19.06%
Alexion Pharmaceuticals16.32%23.16%14.76%

Summary

Alexion Pharmaceuticals beats Fortress Biotech on 9 of the 15 factors compared between the two stocks.


Fortress Biotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$255.71-0.2%$147.24 billion$23.36 billion20.62Insider Selling
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.87-1.6%$84.19 billion$22.45 billion68.94Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$219.39-0.8%$56.78 billion$4.16 billion27.70Analyst Revision
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.60-1.6%$53.84 billion$7.86 billion18.37Analyst Report
Biogen logo
BIIB
Biogen
1.9$270.31-0.0%$41.18 billion$14.38 billion8.95Upcoming Earnings
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$163.68-3.8%$35.98 billion$4.99 billion38.24High Trading Volume
Unusual Options Activity
News Coverage
Gap Down
Seagen logo
SGEN
Seagen
1.7$145.50-2.8%$26.38 billion$916.71 million57.28Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$130.04-0.4%$21.99 billion$876.29 million-58.84
Incyte logo
INCY
Incyte
1.7$82.68-0.6%$18.18 billion$2.16 billion-52.66
Novavax logo
NVAX
Novavax
1.2$227.35-11.1%$16.79 billion$18.66 million-43.55Gap Up
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.88-0.1%$16.29 billion$219.75 million-17.74
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.40-0.8%$14.44 billion$1.70 billion18.17News Coverage
Repligen logo
RGEN
Repligen
1.5$213.30-0.1%$11.68 billion$270.24 million260.12
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.58-1.6%$9.13 billion$788.10 million103.85Analyst Upgrade
Increase in Short Interest
Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.73-1.0%$9.07 billion$1.45 billion19.27Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$23.59-1.5%$7.36 billion$967.78 million49.15
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.41-0.5%$6.65 billion$195.99 million290.06Insider Selling
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46Gap Down
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19Insider Selling
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11Gap Up
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.31-5.3%$2.05 billion$638.60 million-10.50
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Gap Down
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13Analyst Upgrade
Codexis logo
CDXS
Codexis
1.3$23.60-4.0%$1.52 billion$68.46 million-67.43Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Curis logo
CRIS
Curis
1.3$11.49-6.3%$1.05 billion$10 million-14.01Increase in Short Interest
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Gap Down
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.55-0.0%$932.93 million$3.57 million-10.56Analyst Upgrade
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.36-8.8%$812.29 millionN/A0.00Analyst Report
Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.05-3.2%$728.99 million$322.07 million-4.81Decrease in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33-2.7%$716.63 million$150,000.00-4.76
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.28-1.3%$669.56 million$252 million-2.07High Trading Volume
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.98-2.0%$625.09 million$143.01 million-1.14
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58-5.6%$609.03 million$59.29 million-23.87Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$2.62-1.5%$536.28 million$150.05 million-2.40News Coverage
Geron logo
GERN
Geron
1.4$1.47-2.7%$468.24 million$460,000.00-4.20Decrease in Short Interest
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.00-0.7%$461.18 million$109.33 million-2.21
Verastem logo
VSTM
Verastem
1.3$2.68-0.4%$460.07 million$17.46 million-1.90
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.12-7.3%$455.14 million$22.27 million-3.98Analyst Report
Insider Buying
Analyst Revision
News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.3$37.50-0.9%$422.18 million$18.37 million-33.78Increase in Short Interest
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.